We’re announcing the addition of a new program to our genetic medicines pipeline, ALN-F12, an investigational RNAi therapeutic targeting F12 for the treatment of Hereditary Angioedema (HAE). Pre-clinical data for ALN-F12 were presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual meeting, held March 4-7, 2016. HAE is a genetic disorder characterized Read More
“Bleeding Disorders Awareness Month,” was recently approved by the U.S. Department of Health and Human Services (HHS) as a National Health Observance in March. In previous years, March was dedicated to Hemophilia Awareness but through this new initiative, it has been expanded to unite the community and raise awareness of all inherited bleeding disorders and Read More
On Monday, January 11, 2016, John Maraganore presented an updated company overview at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco. You may access the presentation below.
On December 10, 2015, we hosted our third consecutive R&D Day in New York City. Alnylam management and key opinion leaders discussed our most advanced clinical programs, reviewing all the latest data and providing guidance on development plans for the ATTR amyloidosis programs, fitusiran (ALN-AT3), ALN-CC5, ALN-AS1, and ALN-PCSsc.